Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2

Medical Oncology

Volumn 27, Issue 3, 2010, Pages 592-599

  Rubenstein, Marvin ^a,b,c   Tsui, Paulus ^a,b   Guinan, Patrick ^a,b,c,d  

^a Hektoen Institute for Medical Research   (United States)

^b Jr Hospital of Cook County   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense; Breast cancer; Prostate cancer; Therapy

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CLUSTERIN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PROTEIN BCL 2; RAPAMYCIN; TACROLIMUS;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL GROWTH; DRUG EFFICACY; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LD 50; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTERIN; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA, NEOPLASM; SIROLIMUS; SUBSTRATE SPECIFICITY;

EID: 77956898295     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9254-4     Document Type: Article

References (24)

1. M Rubenstein Y Mirochnik P Chow P Guinan 1996 Antisense oligonucleotide intralesional therapy of human PC-3 prostate tumors carried in athymic nude mice J Surg Oncol 62 194 200 10.1002/(SICI)1096-9098(199607)62:3<194::AID- JSO9>3.0.CO;2-2 10.1002/(SICI)1096-9098(199607)62:3<194::AID-JSO9>3.0. CO;2-2 8667627 1:CAS:528:DyaK28XksFyqtbo%3D (Pubitemid 26231490)
2. Rubenstein M, Muchnik S, Dunea G, Chous P, Guinan P. Inoculation of prostatic tumors with antisense oligonucleotides against mRNA encoding growth factors and receptors. In: Einhorn J, Nord CK, Norby SR, editors. Recent advances in chemotherapy. Washington, DC: American Society of Microbiology; 1994. p. 898-9.
3. M Rubenstein Y Mirochnik P Chou P Guinan 1998 Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides Meth Find Clin Pharmacol 20 825 831 10.1358/mf.1998.20.10. 487534 10.1358/mf.1998.20.10.487534 1:CAS:528:DyaK1MXhslymtLY%3D
4. M Rubenstein P Tsui P Guinan 2008 Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and bcl-2 Med Oncol 25 182 186 10.1007/s12032-007-9018-y 10.1007/s12032-007-9018-y 17972023 1:CAS:528:DC%2BD1cXotVOgtbo%3D
5. M Rubenstein R Glick T Lichtor Y Mirochnik P Chou P Guinan 2001 Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor Med Oncol 18 121 130 10.1385/MO:18:2:121 10.1385/MO:18:2:121 11778757 1:CAS:528:DC%2BD3MXptVCjtbo%3D (Pubitemid 32929484)
6. M Rubenstein P Tsui P Guinan 2005 Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors Med Hypotheses 65 905 907 10.1016/j.mehy.2004.12.032 10.1016/j.mehy.2004.12.032 16023790 1:CAS:528:DC%2BD2MXptVeks7c%3D
7. M Rubenstein P Tsui P Guinan 2006 Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy Methods Find Clin Pharmacol 28 1 4
8. M Rubenstein P Tsui P Guinan 2007 Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors Med Oncol 24 189 196 10.1007/BF02698039 10.1007/BF02698039 17848743 1:CAS:528:DC%2BD2sXpsVKls7Y%3D (Pubitemid 350135970)
9. H Zhang JK Kim CA Edwards Z Xy R Taichman C-Y Wang 2005 Clusterin inhibits apoptosis by interacting with activated Bax Nature Cell Biol 7 909 915 10.1038/ncb1291 10.1038/ncb1291 16113678 1:CAS:528:DC%2BD2MXpslaksb0%3D (Pubitemid 41486292)
10. M Redondo T Téllez MJ Roldan A Serrano M García-Aranda ME Gleave ML Hortas M Morell 2007 Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity Breast Cancer Res 9 R86 10.1186/bcr1835 10.1186/bcr1835 18078515
11. Rubenstein M, Tsui P, Guinan P. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors. Comparisons between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel. Med Oncol. 2009;26:124.
12. M Rubenstein KM Anderson P Tsui P Guinan 2006 Synthesis of branched antisense oligonucleotides having multiple specificities: treatment of hormone insensitive prostate cancer Med Hypotheses 67 1374 1379 10.1016/j.mehy.2006.05. 055 10.1016/j.mehy.2006.05.055 1:CAS:528:DC%2BD28XhtVajs77F (Pubitemid 44442657)
13. Weinberg R. The biology of cancer. 16.15 mTOR, a master regulator of cell physiology, represents an attractive target for anti-cancer therapy. New York: Garland Science; 2007. p. 782-787.
14. DM Sabatini 2006 mTOR and cancer: insights into a complex relationship Nat Rev Cancer 6 729 734 10.1038/nrc1974 10.1038/nrc1974 16915295 1:CAS:528:DC%2BD28XosVOmsb8%3D (Pubitemid 44286004)
15. RJ Shaw LC Cantley 2006 Ras, PI(3)K and mTOR signaling controls tumour cell growth Nature 441 424 430 10.1038/nature04869 10.1038/nature04869 16724053 1:CAS:528:DC%2BD28XkvVyrsr8%3D (Pubitemid 44050136)
16. P Amornphimoltham V Patel K Leelahavanichkul RT Abraham JS Gutkind 2008 A retroinhibition approach reveals a tumor cell-autonomous response to Rapamycin in head and neck cancers Cancer Res 68 1144 1153 10.1158/0008-5472.CAN-07-1756 10.1158/0008-5472.CAN-07-1756 18281490 1:CAS:528:DC%2BD1cXhvFemur4%3D (Pubitemid 351272233)
17. NJ Sanfilippo SS Taneja A Chachoua H Lepor SC Formenti 2008 Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer J Clin Oncol 26 2973 2978 10.1200/JCO.2007.14.4105 10.1200/JCO.2007.14.4105 18565883 1:CAS:528:DC%2BD1cXoslOqsL4%3D
18. M Gleave A Tolcher H Miyake C Nelson B Brown E Beraldi J Goldie 1999 Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model Clin Cancer Res 5 2891 2898 10537358 1:CAS:528:DyaK1MXntlGluro%3D (Pubitemid 29493968)
19. M Rubenstein L Slobodskoy Y Mirochnik P Guinan 2003 Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and Taxol Med Oncol 20 29 35 10.1385/MO:20:1:29 10.1385/MO:20:1:29 12665682 1:CAS:528:DC%2BD3sXjtVeltLs%3D (Pubitemid 36344023)
20. P Tsui M Rubenstein P Guinan 2004 Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model Med Oncol 21 339 348 10.1385/MO:21:4:339 10.1385/MO:21:4:339 15579918 1:CAS:528:DC%2BD2MXktlGitA%3D%3D (Pubitemid 40065485)
21. Fluiter K, Frieden M, Vreijling J, Jakobs M., Rosenbohm C, Koch T, Baas F. The properties of novel generation LNA chemistries in antisense oligonucleotides. Effects on biodistribution and efficacy of tumor growth inhibition in vivo. Proc Am Assoc Cancer Res. 2004; 45:Abst 2931.
22. A Janus T Robak P Smolewski 2005 The mammalian target of the Rapamycin (mTOR) kinase pathway; its role in tumourigenesis and target antitumour therapy Cell Mol Biol Lett 10 479 497 16217558 1:CAS:528:DC%2BD2MXht1ehsrrJ
23. CC Hudson M Liu GG Chiang DM Otterness DC Loomis F Kaper AJ Giaccia RT Abraham 2002 Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of Rapamycin Mol Cell Biol 22 7004 7014 10.1128/MCB.22.20.7004-7014.2002 10.1128/MCB.22.20.7004-7014.2002 12242281 1:CAS:528:DC%2BD38XnsFKitrk%3D
24. MB Atkins MK Hidalgo WM Stadler TF Logan JP Dutcher GR Hudes Y Park SH Liou B Marshall JP Boni G Dukart ML Sherman 2004 Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of Rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 909 918 10.1200/JCO.2004.08.185 10.1200/JCO.2004.08.185 14990647 1:CAS:528:DC%2BD2cXpsVKisr0%3D (Pubitemid 41103603)